From discovery to diagnostics, our Simoa assays and custom assay development services can fuel your research through the ability to identify and examine critical biomarkers less invasively, more efficiently, and with higher accuracy when compared to other analog methods.
Simoa assays can detect neurological biomarkers, such as neurofilament light (NfL), Tau, GFAP, and several others associated with brain injury and disease, in blood, serum or plasma. The ability to detect neurological biomarkers at ultra-low levels in blood, serum or plasma, which have traditionally only been detectable in cerebrospinal fluid, has the potential to completely transform the way brain injuries and diseases are detected and diagnosed.
We work with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research, and you could be next.
Quanterix can support your strategic focus in:
Our Recent Successes:
Learn more about the technology and expertise we can supply to fuel your research.
Quanterix offers the flexibility to meet you where your team and research are at.
Utilize our CLIA-certified laboratory as a cost-effective, outsourced solution for your custom biomarker and biopharmaceutical research, assay development, and clinical sample testing.
The Simoa NF-LightTM assay is a digital immunoassay for the quantitative determination of NfL in serum, plasma, and CSF. The antibodies also cross react with murine, bovine, and macaque NfL epitopes, and the assay can be used for research with these species.
Quanterix offers the flexibility of multiplex homebrew assay development to minimize required sample volume; providing full kits that include all reagents and training required to develop these custom homebrew assays.